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Membranous nephropathy is an immune kidney disease caused by IgG antibodies 
that form glomerular subepithelial immune complexes. Proteinuria is mediated by 
complement activation, as a result of podocyte injury by C5b-9, but the role of specific 
complement pathways is not known. Autoantibodies-mediating primary membranous 
nephropathy are predominantly of IgG4 subclass, which cannot activate the classical 
pathway. Histologic evidence from kidney biopsies suggests that the lectin and the 
alternative pathways may be activated in membranous nephropathy, but the pathogenic 
relevance of these pathways remains unclear. In this study, we evaluated the role of 
the alternative pathway in a mouse model of membranous nephropathy. After inducing 
the formation of subepithelial immune complexes, we found similar glomerular IgG 
deposition in wild-type mice and in factor B-null mice, which lack a functional alternative 
pathway. Unlike wild-type mice, mice lacking factor B did not develop albuminuria nor 
exhibit glomerular deposition of C3c and C5b-9. Albuminuria was also reduced but not 
completely abolished in C5-deficient mice. Our results provide the first direct evidence 
that the alternative pathway is necessary for pathogenic complement activation by glo-
merular subepithelial immune complexes and is, therefore, a key mediator of proteinuria 
in experimental membranous nephropathy. This knowledge is important for the rational 
design of new therapies for membranous nephropathy.
Keywords: membranous nephropathy, glomerulonephritis, albuminuria, alternative pathway, membrane attack 
complex, factor B, complement c5, mouse models
inTrODUcTiOn
Membranous nephropathy (MN), one of the leading causes of nephrotic syndrome in adults, is an 
antibody-mediated kidney disease clinically characterized by proteinuria, often heavy and persistent. 
MN is a disease of heterogeneous etiology, defined histologically by immune complexes deposited 
on the subepithelial side of glomerular basement membrane (GBM), together with GBM thickening 
Abbreviations: AP, alternative pathway; GBM, glomerular basement membrane; MN, membranous nephropathy; PLA2R, 
phospholipase A2 receptor; THSD7A, thrombospondin type-1 domain-containing 7A.
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and podocyte foot process effacement, but little glomerular 
inflammation. The most prevalent form is primary MN, now 
understood as an autoimmune disease in which IgG autoantibod-
ies (predominantly of IgG4 subclass) form subepithelial immune 
complexes with autoantigens expressed on podocyte cell surface 
(1, 2). About 70% of patients with primary MN have autoanti-
bodies targeting phospholipase A2 receptor (PLA2R), and an 
additional 3–5% have autoantibodies targeting thrombospondin 
type-1 domain-containing 7A (THSD7A) (3, 4). Secondary MN 
can occur when circulating antibodies bind to antigens planted 
in the subepithelial space, such as cationic bovine serum albumin 
of dietary origin (5).
In the current paradigm for the pathogenesis of MN, comple-
ment activation is a major effector mechanism of subepithelial 
immune complexes (1, 6). Complement activation is initiated by 
three canonical pathways. The classical pathway is triggered by 
immune complexes and the lectin pathway—by certain danger 
patterns, while the alternative pathway (AP) is constitutively 
active and self-amplifies on foreign surfaces. The AP also ampli-
fies activation that is initiated through the other two pathways. 
All three pathways converge toward the assembly of C3 and C5 
convertases, which generate pro-inflammatory anaphylatoxins 
(C3a, C5a), opsonins that mediate immune adhesion (C3b, iC3b), 
and the membrane attack complex (C5b-9), which lyses cells. 
In human MN, C3 fragments and C5b-9 are present alongside 
IgG in subepithelial deposits, while urinary excretion of sC5b-9 
associates with immune disease activity (7–9). Studies in passive 
Heymann nephritis, a faithful rat model of MN, have specifically 
implicated C5b-9 as a key mediator of podocyte injury and 
proteinuria (10, 11). However, the role of different complement 
pathways upstream of C5 activation in human and experimental 
MN remains largely unknown.
How immune complexes activate complement in MN remains 
a conundrum because the autoantibodies implicated in primary 
MN are predominantly of IgG4 subclass (6, 12–14). Although 
immune complexes typically bind C1q and activate the classi-
cal pathway, IgG4 does not bind C1q and is considered unable 
to activate complement—at least not via the classical pathway 
(15–17). In kidney biopsies from patients with primary MN, 
glomerular staining for C1q is almost always weak or absent, 
while staining for mannan-binding lectin (MBL) and C4d is 
usually positive (except in patients with MBL deficiency), con-
sistent with the activation of the lectin pathway (18–20). Beck 
and Salant proposed that the lectin pathway may be activated 
by IgG4 glycoforms that lack terminal galactose and sialic acid, 
and, therefore, can bind MBL (1, 6). However, the occurrence 
of primary MN in patients with MBL deficiency shows that the 
lectin pathway is not absolutely required (21). Glomerular depo-
sition of properdin and factor B—which is indicative of the AP 
activation—is also common in MN (18, 21), but the pathogenic 
relevance of this pathway is not known.
The goal of this study was to determine the contribution of 
the AP to glomerular injury and proteinuria mediated by sub-
epithelial immune complexes. For this purpose, we used a mouse 
model that recapitulates clinical and morphologic features of 
human MN (22–25) and which was found to exhibit proteinuria 
exacerbated by C5 activation. Using Cfb−/− mice, which lack 
factor B (an essential component of the AP), we found that the 
absence of a functional AP prevented complement activation by 
subepithelial immune complexes (as assessed from the glomeru-
lar deposition of C3c and C5b-9) and abolished proteinuria. 
These findings provide the first direct evidence implicating the 
AP activation in the pathogenesis of MN. This knowledge may 
provide a framework for developing new therapeutic strategies 
for MN.
MaTerials anD MeThODs
Materials
The recombinant non-collagenous (NC1) domain of human 
α3(IV) collagen (rh-α3NC1) was expressed in HEK293 cells and 
purified as described (26).
animal experiments
DBA/1J (D1), DBA/2J (D2), and C57Bl/6J (B6) mice were pur-
chased from The Jackson Laboratory (Bar Harbor, ME, USA). 
Breeding pairs of Cfb−/− mice backcrossed on the B6 background 
for more than nine generations (B6.Cfb−/−) were obtained from 
Dr. Joshua Thurman and maintained by homozygous breed-
ing. D1.Cfb−/− mice were generated by backcrossing onto the 
D1 background for four generations and then intercrossing F4 
heterozygous mice. Mice were housed in a specific pathogen-free 
facility with free access to food and water. The study was carried 
out in accordance with the recommendations of the National 
Institutes of Health Guide for Care and Use of Laboratory 
Animals and the protocol was approved by the local Institutional 
Animal Care and Use Committee.
To induce experimental membranous nephropathy, mice 
(6–10 weeks old, both male and female) were immunized subcu-
taneously at two sites on the back with rh-α3NC1 antigen (30 µg 
in 50 µL sterile phosphate-buffered saline) emulsified in an equal 
volume of Complete Freund’s Adjuvant (Sigma, St. Louis, MO, 
USA). D1 and D2 mice received one booster immunization with 
the rh-α3NC1 antigen in Incomplete Freund’s Adjuvant (Sigma, 
St. Louis, MO, USA) on day 21 after the first immunization. B6 
mice were boosted four times with rh-α3NC1 in Incomplete 
Freund’s Adjuvant, at 10 days interval starting on day 14 after the 
first immunization. As negative controls, some mice were immu-
nized with adjuvant alone in each experiment. Unless otherwise 
indicated, mice were euthanized at 8 weeks (for D1 and D2 mice) 
or 12  weeks (for B6 mice) after the initial immunization, and 
tissues and blood were collected for further evaluations.
evaluation of Kidney Function
Spontaneously voided spot urine samples were collected by 
placing mice over 96-well microtiter plates and then analyzed 
as follows. Urinary albumin was measured by capture ELISA 
using a mouse albumin quantitation kit (Bethyl, Montgomery, 
TX, USA). Urine creatinine and blood urea nitrogen levels 
were measured using Infinity creatinine and urea liquid stable 
reagents (Thermo Fisher Scientific, Middletown, VA, USA), 
according to the manufacturer’s protocols. To account for urine 
tonicity, albuminuria was expressed as urinary albumin-to-
creatinine ratio (ACR).
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evaluation of Mouse igg autoantibody 
Production
Sera were assayed for the presence of IgG antibodies to rh-α3NC1 
by ELISA. Briefly, 96-well microtiter plates (Nunc MaxiSorp) were 
coated overnight with rh-α3NC1 (100 ng per well) in carbonate-
bicarbonate buffer, pH 9.6. After blocking with 1% bovine serum 
albumin, the wells were incubated for 1 h with mouse sera diluted 
1/5,000 for detection of total IgG, 1/2,000 for detection of IgG1, 
or 1/500 for detection of IgG2a and IgG2b. Secondary antibod-
ies were alkaline phosphatase-conjugated goat anti-mouse IgG 
(Rockland Immunochemicals, Gilbertsville, PA, USA) and 
horseradish peroxidase-conjugated goat anti-mouse IgG1, IgG2a, 
IgG2b, or IgG2c (Bethyl, Montgomery, TX, USA). Plates were 
developed with p-nitrophenol phosphate or tetramethylbenzidine 
(Sigma, St. Louis, MO, USA) as substrate, and absorbance was 
read at 405 nm with a SpectraMax ELISA plate reader (Molecular 
Devices, Sunnyvale, CA, USA).
renal histopathology and 
immunofluorescence Microscopy
For light microscopy, portions of mouse kidneys were fixed in 
10% buffered formalin, dehydrated through a graded ethanol 
series, and embedded in paraffin. Paraffin sections (2 µm thick) 
were stained with periodic-acid Schiff reagent. Transmission 
electron microscopy was performed as described (27). For 
immunofluorescence, portions of mouse kidneys embedded 
in OCT were snap-frozen in isopentane and stored at −70°C. 
Cryosections cut at a thickness of 5  µm were fixed in cold 
acetone for 10  min. Mouse IgG was visualized using FITC-
conjugated goat anti-mouse IgG (BD Bioscience Pharmingen, 
San Jose, CA, USA). Complement C3 was visualized using FITC-
conjugated goat anti-mouse C3c (Nordic Immunology, Tilburg, 
Netherlands). Kidney deposition of rh-α3NC1 was visualized 
with rat IgG mAb RH34 (a gift from Dr. Yoshikazu Sado, Shigei 
Medical Research Institute, Japan), which is specific for human 
but not mouse α3NC1 (28). Mouse C5b-9, properdin, factor 
H, and C4 were visualized using rabbit anti-C5b9 (Abcam; 
Cambridge, MA, USA), rabbit anti-properdin (Santa Cruz, CA, 
USA), rat IgG anti-mouse C4d mAb (HyCult, Netherlands), and 
rat IgG anti-mouse factor H mAb (MAB4999, R&D Systems, 
Minneapolis, MN, USA). Nephrin was visualized using guinea 
pig anti-nephrin (Progen, Germany). Heparan sulfate chains 
were visualized with mouse IgM mAb JM403 (29). Agrin was 
visualized using a rabbit anti-agrin polyclonal antibody (kindly 
provided by Dr. Takako Sasaki, Oita University, Japan), as 
previously described (27). Secondary antibodies were Alexa 
Fluor 488-conjugated goat anti-rabbit IgG, goat anti-rat IgG, 
donkey anti-guinea pig IgG, goat anti-mouse IgM (Invitrogen, 
Carlsbad, CA, USA), and FITC-goat anti-rat IgG (BD Bioscience 
Pharmingen, San Jose, CA, USA). Sections were mounted with 
anti-fade reagent (Invitrogen, Carlsbad, CA, USA), then cover-
slipped and observed using a fluorescence microscope (Nikon 
Eclipse E800). Photomicrographs were captured with a digital 
camera attached to the microscope, using the same exposure 
settings for each primary antibody. For quantitative analyses, 
images were analyzed with Image J software, as described (30). 
All sections from one experiment were stained and analyzed at 
the same time.
In Vitro complement activation
Fresh frozen normal mouse serum, collected from DBA/1 mice, 
and stored in aliquots at −70°C, was used as a source of comple-
ment. Cryosections of mouse kidneys fixed in cold acetone were 
incubated overnight at 37°C with normal mouse serum diluted 1:3 
in veronal buffered saline (Sigma, St. Louis, MO, USA) containing 
0.1% Tween 20 and supplemented with: (a) 2.5 mM calcium chlo-
ride and 0.7 mM magnesium chloride; or (b) 2.5 mM magnesium 
chloride and 6.2 mM EGTA; or (c) 25 mM EDTA. Complement 
activation was visualized by staining with FITC-conjugated goat 
anti-mouse C3c, as described above.
statistical analyses
Analyses were performed using GraphPad Prism 7.00 software 
(San Diego, CA, USA). ACRs were log transformed. The signifi-
cance of differences was determined by unpaired t test or by one-
way analysis of variance (ANOVA) with Dunnett’s correction 
for multiple comparisons. A value of P <  0.05 was considered 
statistically significant. Values are presented as means ± SEM.
resUlTs
complement c5 Deficiency ameliorates 
albuminuria induced by subepithelial 
immune complexes in Mice immunized 
With α3nc1
DBA/1 (D1) mice immunized with α3NC1 develop kidney dis-
ease recapitulating clinical and morphologic features of human 
MN (22–25). This model exhibits proteinuria associated with 
subepithelial immune complexes and glomerular deposition of 
IgG, C3, and C5b-9, but the role of complement activation in 
proteinuria is not known. We reasoned that if C5b-9 is pathogenic 
in this mouse model (analogous to the rat Heymann nephritis 
model), then, proteinuria would be ameliorated by the genetic 
deficiency of complement C5, which occurs naturally in several 
inbred strains of mice (31). To test this conjecture, we induced 
experimental MN in C5-deficient DBA/2 (D2) mice, which are 
nearly 95% genetically identical to C5-sufficient D1 mice (32).
Compared to D1 mice, D2 mice immunized with α3NC1 
developed much milder albuminuria (Figure  1A). At week 8 
after the first immunization, the endpoint for this experiment, 
the urine ACR in α3NC1-immunized D2 mice (2.4 ± 0.96) was 
significantly lower (P < 0.001) than that in α3NC1-immunized 
D1 mice (77.1 ±  20.8), albeit greater than in control D2 mice 
immunized with adjuvant alone (ACR 0.16 ± 0.07) (Figure 1B). 
Blood urea nitrogen levels did not increase over the baseline 
(mean values at week 0 and at week 8 were 23.1 and 20.3 mg/dL 
for D1 mice, 27.8 and 25.4 mg/dL for D2 mice), indicating that 
the renal function did not decline during the duration of the 
experiment. Serum levels of mouse IgG anti-α3NC1 antibodies 
were similar in D1 and D2 mice (data not shown). Kidneys were 
collected at 8 weeks post-immunization for morphologic evalua-
tion. By light microscopy, kidneys from α3NC1-immunized mice 
FigUre 1 | C5 deficiency protects against albuminuria in experimental MN. 
(a) Time course of urinary albumin-to-creatinine ratio (ACR) in D1 mice 
(circles) and D2 mice (squares) immunized with α3NC1 (N = 5–7 per group). 
Control D2 mice (triangles) were immunized with adjuvant alone (N = 3). 
Shown are means and SEM. (B) Scatterplot depicting the final ACR values 
(at week 8). The significance of differences among groups was analyzed by 
one-way ANOVA with Dunnett’s correction for multiple comparisons. 
***P < 0.001, ****P < 0.0001. n.s., not significant. (c) Light microscopy 
shows normal appearance of glomeruli and tubules in α3NC1-immunized D2 
and D1 mice (periodic acid–Schiff staining; original magnification 400×). (D) 
Transmission electron microscopy shows subepithelial electron dense 
deposits (arrowhead), areas of glomerular basement membrane (G) 
thickening, and effacement of podocyte (Po) foot processes. Original 
magnification 7,500×.
FigUre 2 | Analysis of glomerular immune complexes and complement 
deposition in D1 and D2 mice immunized with α3NC1. Kidneys were 
collected at week 8 post-immunization from adjuvant immunized D2 mice 
(left), α3NC1-immunized D2 mice (middle), and α3NC1-immunized D1 mice 
(right). (a) Direct immunofluorescence staining shows mouse IgG binding 
along the glomerular basement membrane (GBM) in α3NC1-immunized D1 
and D2 mice. Control mice show non-specific mesangial deposition of 
mouse IgG. (B) Mean fluorescence intensity (MFI) of IgG staining, expressed 
in arbitrary units (AU), was compared in α3NC1-immunized D2 and D1 mice. 
The difference was not significant (n.s.) by t test. (c) Indirect 
immunofluorescence staining with mAb RH34 shows GBM deposition of 
exogenous antigen in all α3NC1-immunized mice, which is absent in 
adjuvant-immunized mice. (D) Direct immunofluorescence staining reveals 
C3c deposition along the capillary loops in α3NC1-immunized D1 and D2 
mice. In control mice, C3c staining is positive in the Bowman’s capsule and 
kidney tubules. (e) Indirect immunofluorescence shows capillary loop staining 
for C5b-9 in α3NC1-immunized D1 mice. A weak background of non-specific 
immunofluorescence is observed in adjuvant-immunized and α3NC1-
immunized D2 mice. Original magnification 400×.
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appeared relatively normal, with little glomerular inflammation 
(Figure  1C); however, electron microscopy revealed areas of 
thickened GBM surrounding subepithelial deposits and podocyte 
foot process effacement (Figure 1D).
Immunofluorescence microscopy showed mouse IgG staining 
along the GBM in all α3NC1-immunized mice (Figure 2A). The 
IgG staining intensity was similar in D1 and D2 mice (Figure 2B). 
Staining with an antibody that binds to human but not mouse 
α3NC1 (mAb RH34) showed capillary loop deposition of 
exogenous antigen in α3NC1-immunized but not control mice 
(Figure 2C). GBM staining for C3c, which indicates recent com-
plement activation, was also found in all α3NC1-immunized 
mice (Figure  2D). However, glomerular deposition of C5b-9 
was only found in α3NC1-immunized D1 mice (Figure 2E), as 
expected based on the C5 deficiency in D2 mice. A decrease 
in nephrin staining in α3NC1-immunized D1 mice compared 
to D2 mice confirmed an injured podocyte phenotype (not 
shown). These results imply that C5 activation exacerbates 
proteinuria induced by subepithelial immune complexes in 
FigUre 3 | Histologic evidence of AP activation in experimental MN. 
Glomerular deposition of properdin (a), factor H (B), and C4d (c) was 
evaluated by indirect immunofluorescence staining of frozen kidney sections 
from α3NC1-immunized D1 mice and adjuvant-immunized control mice. 
Properdin and factor H staining along the capillary loops was found in 
α3NC1-immunized D1 mice, but not in adjuvant-immunized mice. Mesangial 
C4d staining was found in all mice, while weaker segmental staining for C4d 
along capillary loops was also present in α3NC1-immunized mice.
FigUre 4 | B6.Cfb−/− mice immunized with α3NC1 are protected against 
albuminuria despite developing subepithelial immune complexes. (a) Time 
course of urinary albumin-to-creatinine ratio (ACR) in B6.Cfb+/+ mice (circles) 
and B6.Cfb−/− mice (squares) immunized with α3NC1 (N = 7 per group). 
Control B6 mice (triangles), including both genotypes, were immunized with 
adjuvant alone (N = 7). Shown are means and SEM. (B) Scatterplot depicts 
the ACR values at the endpoint of this experiment (week 12). The significance 
of differences among groups was analyzed by one-way ANOVA with 
Dunnett’s correction for multiple comparisons. ***P < 0.001, ****P < 0.0001. 
n.s., not significant. (c) Morphology of kidneys from α3NC1-immunized 
B6.Cfb−/− and B6.Cfb+/+ mice appears normal by light microscopy (periodic 
acid–Schiff staining, original magnification 400×). (D) Transmission electron 
microscopy shows subepithelial electron dense deposits (arrowhead), 
expansion of the glomerular basement membrane (G), and podocyte (Po) 
foot process effacement. Original magnification 7,500×.
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α3NC1-immunized mice, presumably as a result of podocyte 
injury by C5b-9.
evidence of the aP activation by 
subepithelial immune complexes
To determine which complement pathways may be activated by 
subepithelial immune complexes, we assessed glomerular deposi-
tion of properdin, factor H, and C4d. Properdin and factor H 
are positive and negative regulators of the AP, respectively, while 
C4d is a marker of the classical and lectin pathway activation. 
Capillary loop staining for both properdin (Figure 3A) and factor 
H (Figure 3B) was found in α3NC1-immunized D1 mice but not 
in control mice. All mice had staining for C4d in a non-specific 
mesangial pattern (Figure 3C), also commonly seen in normal 
human glomeruli (33). In addition, α3NC1-immunized mice 
also had segmental staining for C4d along the capillary loops, 
suggesting that subepithelial immune complexes formed in these 
mice activate multiple complement pathways, similar to what is 
observed in human MN (18). While these results are indicative 
of the AP activation, the pathogenic relevance of the AP cannot 
be inferred from morphologic findings alone.
B6.cfb−/− Mice immunized With α3nc1 
Develop subepithelial immune complexes 
but are Protected against albuminuria 
and Do not exhibit glomerular 
complement Deposition
The absence of a functional AP in Cfb−/− mice afforded a strategy 
to investigate the role of the AP in experimental MN. We initially 
obtained Cfb−/− mice backcrossed on the B6 background for nine 
generations (B6.Cfb−/−), which allowed us to compare the course 
of albuminuria induced by α3NC1 immunization in B6.Cfb−/− 
mice to congenic wild-type B6 mice (B6.Cfb+/+) (Figure  4A). 
At the endpoint in this experiment (i.e., at 12  weeks after the 
initial immunization), the urinary ACR in α3NC1-immunized 
B6.Cfb−/− mice (0.11 ±  0.05) was similar to that in adjuvant-
immunized B6 mice (0.057 ±  0.011); both were significantly 
lower (P < 0.0001) than the urine ACR in α3NC1-immunized 
B6.Cfb+/+ mice (10.6 ±  5.9) (Figure  4B). Two mice from each 
group were observed for an additional 4  weeks; albuminuria 
further increased in Cfb+/+ mice but not in Cfb−/− mice. In both 
groups of α3NC1-immunized B6 mice, kidney morphology mice 
appeared relatively normal by light microscopy (Figure  4C). 
FigUre 6 | Analysis of glomerular immune complexes and complement 
deposition in B6 mice immunized with α3NC1. Kidneys from adjuvant-
immunized B6 mice (left), α3NC1-immunized B6.Cfb−/− mice (middle), and 
α3NC1-immunized B6.Cfb−/− mice (right) were collected at week 12 after the 
initial immunization. (a) Immunofluorescence staining for mouse IgG shows 
glomerular basement membrane (GBM) staining in α3NC1-immunized 
B6.Cfb−/− and B6.Cfb+/+ mice. Adjuvant-immunized mice show non-specific 
mesangial IgG deposition. (B) Mean fluorescence intensity (MFI) of IgG 
staining, expressed in arbitrary units (AU), was compared in α3NC1-
immunized B6.Cfb−/− and B6.Cfb+/+ mice. Significance was evaluated by t 
test (n.s., not significant). (c) Staining with mAb RH34 shows GBM 
deposition of exogenous antigen in α3NC1 immunized B6.Cfb−/− and B6.
Cfb+/+ mice, which is absent in control mice. (D) Direct immunofluorescence 
staining reveals C3c deposition in a capillary loop pattern in α3NC1-
immunized B6.Cfb+/+ mice. C3c staining is absent in B6.Cfb−/− mice. (e) 
Indirect immunofluorescence shows C5b-9 deposition along the GBM in 
α3NC1-immunized B6.Cfb+/+ mice, but not B6.Cfb−/− mice. Original 
magnification 400×.
FigUre 5 | Analysis of circulating anti-α3NC1 mouse IgG antibodies. The 
levels of circulating mouse IgG, IgG1, IgG2b, and IgG2c antibodies binding  
to rh-α3NC1 were measured by indirect ELISA. Mouse sera were diluted 
1/5,000 for total IgG, 1/2,000 for IgG1, and 1/500 for IgG2b and IgG2c.  
The significance of differences between Cfb−/− (KO) and Cfb+/+ (WT) mice  
was evaluated by t-test (n.s., not significant).
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Electron microscopy showed features of MN including sub-
epithelial deposits, GBM expansion, and foot process effacement 
(Figure 4D).
Humoral immune responses to α3NC1 were comparable in 
immunized B6.Cfb−/− and B6.Cfb+/+ mice, as shown by similar levels 
of circulating mouse IgG, IgG1, IgG2b, and IgG2c anti-α3NC1 anti-
bodies (Figure 5). Immune complexes and complement deposition 
were evaluated by immunofluorescence microscopy (Figure  6). 
GBM staining for mouse IgG was found in all α3NC1-immunized 
mice (Figure 6A), with similar intensity in B6.Cfb−/− and B6.Cfb+/+ 
mice (Figure  6B). GBM deposition of exogenous antigen in 
α3NC1-immunized mice was indicated by positive staining with 
mAb RH34 (Figure 6C). Deposition of C3c along the GBM was 
found in α3NC1-immunized Cfb+/+ mice but was completely 
absent in immunized Cfb−/− mice (Figure 6D); as also found for 
C5b-9 (Figure 6E). These results indicate that the absence of factor 
B does not affect the formation of subepithelial immune complexes 
but prevents glomerular complement activation and abolishes 
proteinuria induced by immunization with α3NC1.
absence of Proteinuria and glomerular 
complement Deposition in D1.cfb−/− Mice 
immunized With α3nc1 corroborates  
the Pathogenic role of the aP in 
experimental Mn
We sought to verify whether the ablation of the AP also prevents 
albuminuria in D1 mice, which are more susceptible to MN. 
Results in B6 mice cannot be directly compared to those in D1 
and D2 mice because B6 mice are more resistant to experimental 
kidney disease and develop milder proteinuria requiring repeated 
immunizations with α3NC1. After backcrossing to D1 for four 
generations, we generated D1.Cfb−/− mice, which had about 
94% D1 genetic background (comparable to almost 95% genetic 
similarity between D1 and D2 mice).
D1.Cfb−/− mice were resistant to development of albumi-
nuria induced by α3NC1 immunization (Figure  7A). At the 
final time point (at week 8 post-immunization), urine ACR in 
α3NC1-immunized D1.Cfb−/− mice (0.36 ±  0.12) was similar 
to that in adjuvant-immunized D1 mice (0.078  ±  0.023); 
both were significantly lower (P < 0.0001) than urine ACR in 
α3NC1-immunized D1.Cfb+/+ mice (78.8 ± 18.1) (Figure 7B). 
Morphologic analyses of the kidneys collected at week 8 largely 
recapitulated the findings from B6 mice. Light microscopy did 
not show major glomerular abnormalities (Figure  7C), while 
electron microscopy showed subepithelial deposits with GBM 
thickening and effaced podocyte foot processes (Figure  7D). 
GBM staining for mouse IgG was found in all α3NC1-
immunized but not control mice (Figure  8A). The IgG 
FigUre 7 | D1.Cfb−/− mice immunized with α3NC1 are protected against 
albuminuria despite developing subepithelial immune complexes. (a) Time 
course of urinary albumin-to-creatinine ratio (ACR) in D1.Cfb+/+ mice (circles) 
and D1.Cfb−/− mice (squares) immunized with α3NC1 (N = 7–8 per group). 
Control D1 mice (triangles), including both genotypes, were immunized with 
adjuvant alone (N = 5). Shown are means and SEM. (B) Scatterplot depicts 
the ACR values at the last time point (week 8). The significance of differences 
among groups was analyzed by one-way ANOVA with Dunnett’s correction 
multiple comparisons. ***P < 0.001, ****P < 0.0001, n.s., not significant.  
(c) Morphology of kidneys from α3NC1-immunized D1.Cfb−/− (left) and D1.
Cfb+/+ mice (right) appeared normal by light microscopy (periodic acid–Schiff 
staining, original magnification 400×). (D) Transmission electron microscopy 
shows subepithelial electron dense deposits (arrowhead), thickening of the 
glomerular basement membrane (G), and podocyte (Po) foot process 
effacement. Original magnification 15,000×.
FigUre 8 | Analysis of glomerular immune complexes and complement 
deposition in D1 mice immunized with α3NC1. Kidneys were collected from 
adjuvant immunized D1 mice (left), α3NC1-immunized D1.Cfb−/− mice 
(middle), and α3NC1-immunized D1.Cfb−/− mice (right) at week 8 after the 
initial immunization. (a) Immunofluorescence staining for mouse IgG shows 
glomerular basement membrane (GBM) staining in α3NC1-immunized 
D1.Cfb−/− and D1.Cfb+/+ mice. Adjuvant-immunized control mice show 
non-specific mesangial IgG deposition. (B) Mean fluorescence intensity  
(MFI) of IgG staining, expressed in arbitrary units (AU), was compared in 
α3NC1-immunized D1.Cfb−/− and D2.Cfb+/+ mice. The difference was not 
significant (n.s.) by t test. (c) Staining with mAb RH34 shows the GBM 
deposition of exogenous antigen in both groups of α3NC1-immunized mice, 
which is absent in control mice. (D) Direct immunofluorescence staining 
reveals capillary loop deposition of C3c in α3NC1-immunized D1.Cfb+/+  
mice, while C3c staining is absent in D1.Cfb−/− mice. (e) Indirect 
immunofluorescence shows C5b-9 deposition along the GBM in  
α3NC1-immunized D1.Cfb+/+ mice but not D1.Cfb−/− mice. Original 
magnification 400×.
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staining intensity was similar in D1.Cfb−/− and D1.Cfb+/+ mice 
(Figure 8B). Staining with mAb RH34 showed GBM deposition 
of exogenous antigen in these mice (Figure 8C). Capillary loop 
deposition of C3c (Figure 8D) and C5b-9 staining (Figure 8E) 
was observed in α3NC1-immunized D1.Cfb+/+ mice but was 
absent from α3NC1 immunized D1.Cfb−/− mice. These results 
confirm that the AP is essential for pathogenic complement 
acti vation by subepithelial immune complexes and further 
show that the ablation of the AP abolishes proteinuria to a 
greater extent than C5 deficiency under comparable experimental 
conditions.
subepithelial immune complexes activate 
complement In Vitro via the aP
Since α3NC1-immunized Cfb−/− mice had glomerular IgG but 
not C3c deposition, we investigated whether immune complexes 
formed in these mice can activate complement in vitro. To this 
end, kidney cryosections from D1.Cfb−/− mice were incubated 
with normal mouse serum as a source of complement. As shown 
in Figure  9, glomerular capillary loops deposition of C3c was 
found after incubation with normal mouse serum in the presence 
of Ca2+ and Mg2+ (in which all three pathways are active), and also 
in the presence of Mg2+ and EGTA (conditions under which the 
FigUre 10 | Decreased glomerular basement membrane (GBM) staining  
by anti-heparan sulfate mAb JM403 in experimental MN. (a) Immuno-
fluorescence staining with anti-heparan sulfate mAb JM403 revealed intense 
staining in the GBM of control mice, which was markedly decreased in 
α3NC1-immunized B6.Cfb+/+ mice. (B) GBM staining for agrin core protein 
was similar in both groups.
FigUre 9 | In vitro complement activation by glomerular immune complexes 
from α3NC1-immunized Cfb−/− mice. Immunofluorescence analysis of C3c 
deposition onto kidneys cryosections from α3NC1-immunized D1.Cfb−/−  
mice (left) and control non-immunized wild-type DBA/1 mice (right), after 
incubation with 33% normal mouse serum in buffer containing Ca2+ and Mg2+ 
(a), Mg2+ and EGTA (B), or EDTA (c). Complement pathways active in each 
buffer are indicated on the left, according to the key shown at the bottom.
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alternative pathway is active, but the classical and lectin pathways 
are inhibited), but not in the presence EDTA (which inhibits all 
thee pathways). In control experiments using kidney cryosec-
tions from a non-immunized wild-type mouse (i.e., without 
glomerular IgG deposits), no C3c deposition along the capillary 
loops was observed under any conditions. Similar results were 
obtained using human serum as complement source (not shown). 
These results indicate that glomerular immune complexes formed 
in vivo in α3NC1-immunized Cfb−/− mice have the intrinsic abil-
ity to activate complement via the AP.
The loss of gBM heparan sulfate in 
experimental Mn May affect the local  
aP regulation
Activation of the AP on extracellular matrices, which are not pro-
tected by intrinsic complement regulators, is largely controlled by 
factor H. Factor H selectively inhibits the AP on host surfaces by 
recognizing polyanions such as heparan sulfate as markers of self. 
The normal GBM contains heparan sulfate chains attached to the 
agrin core protein, but the GBM staining for heparan sulfate epitopes 
is markedly decreased in human MN and rat Heymann nephritis 
(34–36). We investigated whether similar changes occur after the 
induction of experimental MN in mice. Compared to adjuvant-
immunized control mice, α3NC1-immunized B6 (Figure 10) 
and D1 mice (not shown) with proteinuria had almost complete 
loss of GBM staining by anti-heparan sulfate mAb JM403, while 
staining for agrin core protein was not changed. These results 
demonstrate the loss of heparan sulfate epitopes from the GBM 
of α3NC1-immunized mice, which may locally dysregulate the 
AP by reducing the recruitment of factor H (37).
DiscUssiOn
Whereas podocyte injury by C5b-9 is a major effector mechanism 
of the subepithelial immune complexes that lead to proteinuria 
in MN, the role of specific complement pathways upstream of C5 
activation remains poorly understood. Glomerular deposition of 
complement components specific to the AP in human MN raises 
the question of whether the AP activation is pathogenically 
relevant or just an epiphenomenon. We addressed this question 
by evaluating how the absence of a functional AP affects kidney 
disease in a mouse model of MN. We found that Cfb−/− and Cfb+/+ 
mice immunized with α3NC1 developed subepithelial immune 
complexes, with similar IgG deposition. However, Cfb−/− mice 
were protected against proteinuria and did not exhibit glomerular 
deposition of C3c and C5b-9. These results imply that the AP is 
required for glomerular complement activation by subepithelial 
immune complexes, which in turn is necessary for proteinuria. 
We thus provide the first direct evidence implicating the AP in 
the pathogenesis of experimental MN.
Complement activation can contribute to kidney disease at 
several levels, by causing direct injury at the glomerular filtration 
barrier, and also by augmenting the production of pathogenic 
antibodies (38). The latter appears unlikely in our model, as the 
levels of circulating anti-α3NC1 antibodies and kidney-bound 
IgG were similar in Cfb−/− and wild-type mice. Hence, the more 
likely mechanism by which the absence of factor B protects against 
proteinuria is via the reduced complement activation at the level 
of C3 and C5, as implied by the absence of glomerular C3c and 
C5b-9 staining in Cfb−/− mice despite the presence of subepithelial 
immune deposits. While immune complexes typically activate 
complement via the classical pathway, the AP is secondarily 
activated and forms an amplification loop. In a quantitative assay 
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of complement activation initiated via the classical pathway 
(by IgM or aggregated IgG), the AP accounted for more than 
80% of the C5 activation products (C5a, sC5b-9) generated in 
the assay (39). This amplification explains the pathogenic role of 
the AP in various animal models of immune complex-mediated 
diseases, including lupus nephritis (40–42). An increased genera-
tion of C3b would exacerbate the formation of C5b-9, which is 
pathogenic in MN, because C5 binding to C3b is a prerequisite 
for C5 activation, and very high affinity C5 convertases only form 
at high surface density of C3b (43, 44).
How glomerular immune complexes activate complement 
depends on several factors, including their ultrastructural locali-
zation and immunoglobulin composition. In human anti-GBM 
disease, IgG1 auto-antibodies that bind to α345(IV) collagen in 
the human GBM (usually specific for α3NC1) cause severe glo-
merulonephritis, often featuring C3 deposition along the GBM 
(45). By contrast, in wild-type mice, human or murine IgG 
antibodies that bind to α345(IV) collagen in the mouse GBM are 
insufficient to cause local complement activation or glomerular 
injury (46, 47). It is, therefore, remarkable that subepithelial 
immune complexes formed by mouse IgG anti-α3NC1 antibod-
ies with exogenous rh-α3NC1 antigen (via a planted antigen 
mechanism) are able to activate complement in vivo and in vitro, 
even though anti-α3NC1 antibodies are predominantly of mouse 
IgG1 subclass. Mouse IgG1 functionally resembles human IgG4 
(the predominant IgG subclass in human primary MN), in that 
neither binds C1q to activate the classical pathway (48). However, 
mouse IgG1 can activate the AP (49), as do human IgG2 and 
IgA (50). Whether human IgG4 can activate the AP remains an 
important question yet to be solved. In preliminary studies, we 
found that the AP amplifies in  vitro complement activation by 
immune complexes formed by human anti-PLA2R IgG autoanti-
bodies (Dorin-Bogdan Borza and Laurence H. Beck, unpublished 
observations).
The extent to which the AP is activated is also modulated by 
the local microenvironment. Although the AP is constitutively 
active and self-amplifies on foreign surfaces, its activation on 
self-surfaces is normally restricted by host complement regula-
tory proteins that inactivate C3 and C5 convertases. In glomeruli, 
podocytes are protected by membrane-bound regulators such as 
CR1, while plasma factor H is recruited to inhibit the AP in the 
GBM (51). Studies in the nephrotoxic nephritis model, in which 
the AP contributes to chronic but not acute kidney injury, suggest 
that the mechanisms controlling the AP may be impaired over 
time by the persistence of antibodies or by glomerular injury (52). 
One mechanism that could locally dysregulate the AP is the loss 
of heparan sulfate chains, which factor H normally recognizes as 
markers of self (37). Decreased GBM staining by anti-heparan 
sulfate mAb JM403 occurs in α3NC1-immunized mice (this 
study) and also in human MN (53) and a rat model of MN, active 
Heymann nephritis (36). The loss of GBM heparan sulfate may 
be the result of enzymatic cleavage by heparanase, which is often 
upregulated in glomerular disease (54), including in Heymann 
nephritis (55). It may also be due to other mechanisms (56). An 
apparent loss of heparan sulfate occurs in lupus nephritis due to 
masking by immune complexes (57). Besides factor H, heparan 
sulfate can also bind properdin, thus serving as a platform for AP 
activation on some surfaces, such as the apical surface of kidney 
tubules or apoptotic T cells (58, 59). In our model, given the loss 
of GBM heparan sulfate, glomerular deposition of properdin is 
more likely due to properdin binding to C3b and stabilization of 
the C3bBb convertase (60). Elucidating the relationships among 
the loss of GBM heparan sulfate, local complement regulation 
and proteinuria is an area for future investigations.
The role of C5b-9 in proteinuria induced by subepithelial 
immune complexes has been demonstrated in passive Heymann 
nephritis (11), but not validated in other models of MN to date. 
In this study, we found that C5-deficient DBA/2 mice developed 
significantly less proteinuria than C5-sufficient DBA/1 mice, 
which further supports the paradigm that C5 activation mediates 
glomerular injury by subepithelial immune complexes. Cleavage 
of C5 generates C5b, a precursor for C5b-9, and also C5a, a 
pro-inflammatory anaphylatoxin. Although our results cannot 
formally exclude a pathogenic role for C5a in the MN model used 
in this study, there is currently no evidence to implicate C5a as 
meditator of glomerular injury in MN, and inflammatory cells are 
usually not detected in glomeruli in MN.
An unexpected finding in this study was that the absence of 
factor B abolished proteinuria to a greater extent than the absence 
of complement C5. Under similar experimental conditions, 
albuminuria in C5-deficient D2 mice (ACR 2.38 ±  0.96) was 
reduced by a factor of about 30 compared to C5-sufficient D1 
mice (ACR 77.1 ±  20.8), while albuminuria in D1.Cfb−/− mice 
(ACR 0.36 ± 0.12) was reduced by a factor of about 200 compared 
to D1.Cfb+/+ mice (ACR 78.8 ± 18.1)—a sixfold difference. This 
difference may be explained by the fact the absence of C5 only 
prevents events downstream of C5 activation (such as C5b-9 for-
mation), while the absence of factor B also inhibits complement 
activation at the level of C3. Indeed, glomerular C3c deposition 
was absent in Cfb−/− mice but present in C5-null mice. These 
results suggest that complement activation at the level of C3 may 
also contribute to proteinuria in MN, independently of C5b-9-
mediated glomerular injury.
Our study has some limitations. The role of the AP in experi-
mental MN was only investigated using genetic approaches. 
Further corroboration by pharmacologic inhibition of the AP in 
a clinically relevant setting is desirable. This is evaluated in ongo-
ing studies. Another potential caveat is that subepithelial immune 
complexes induced by immunization with α3NC1 are formed 
by a planted antigen mechanism, recapitulating secondary MN 
rather than primary MN. Nonetheless, glomerular deposition of 
factor B occurs not only in primary but also secondary MN (6), 
suggesting that the AP is involved regardless of how subepithelial 
immune complexes form. We expect that future studies will 
address the pathogenic role of the AP in emerging animal models 
of MN, which target autoantigens implicated in human disease. Of 
interest in this regard, mice injected with human anti-THSD7A 
antibodies develop mild proteinuria with histologic features of 
MN (61). However, efforts to develop models of MN targeting 
PLA2R have been hampered by the fact that rodents (unlike 
humans) do not express PLA2R on podocytes.
A better understanding of the complement-mediated mecha-
nisms of injury in MN may help develop novel therapies for 
MN. MN is a common cause of nephrotic syndrome in adults, 
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and up to 40% of patients eventually develop end-stage renal 
disease (62). Current therapies use non-specific immunosup-
pressive drugs, which have significant toxic side effects and are 
ineffective in about 25–30% of patients (2, 63, 64). Therapeutic 
inhibition of complement may be a viable approach for treating 
MN (65), especially in patients who do not respond to conven-
tional therapy or have rapid deterioration of renal function. One 
anti-complement agent already in clinical use is eculizumab, 
a humanized IgG2/IgG4 anti-C5 monoclonal antibody that 
blocks C5 activation. An early, unpublished clinical trial of 
eculizumab in primary MN did not find a significant remis-
sion of proteinuria after 16 weeks of treatment, which may be 
explained by the insufficient dosage of the drug. Indeed, a recent 
study has found that C5 inhibition by eculizumab is incomplete 
at high C3b density (44), a setting relevant to MN. Compared 
to eculizumab, which does not prevent potentially harmful C3 
activation, agents that inhibit complement at the level of both 
C3 and C5 may offer additional therapeutic benefit. The results 
of this study identify the AP as a novel target for therapy in MN. 
Inhibition of the AP has the advantage of leaving the classical 
and lectin pathways intact for defense against pathogens and 
other homeostatic functions.
In summary, our results suggest that the AP is necessary 
for sustained complement activation by subepithelial immune 
complexes, leading to glomerular deposition of C3c and C5b-9. 
Furthermore, the activation of the AP is essential for the devel-
opment of proteinuria in experimental MN. These findings may 
provide a framework for the rational design of new therapies for 
MN.
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